Mixed hematopoietic chimerism following bone marrow transplantation for hematologic malignancies.
Twenty-nine of 172 patients (17%) who received an allogeneic bone marrow transplant (BMT) from histocompatible sibling donors for hematologic malignancies were mixed hematopoietic chimeras; ie, they had a mixture of donor and host hematopoietic or lymphohematopoietic cells at greater than or equal to 14 days after transplantation. Twenty-four of the 29 mixed chimeras (83%) have remained in continuous complete remission for up to 116 months (greater than 9 years) following BMT. Four of the 29 patients (14%) have had recurrent leukemia, and 7 of the 29 (24%) have had moderate or severe graft-v-host disease (GVHD). Twelve of these 29 patients have persisted as stable mixed chimeras for greater than or equal to 2 years after BMT, whereas other patients converted to all donor-type hematopoiesis. The incidence of mixed chimerism was independent of the pretransplant regimen, the donor or recipient age (less than 20 v greater than 20 years), remission status (first complete remission of acute leukemia and first chronic phase of chronic myelocytic leukemia v later stages of disease), and type of leukemia. Our data indicate that mixed hematopoietic chimerism is not rare after BMT for hematologic malignancies and that its presence is compatible with long-term disease-free survival. Prospective studies of mixed chimerism after BMT are warranted to achieve better understanding of its biologic importance.
Petz
L D
LD
Department of Clinical and Experimental Immunology, City of Hope National Medical Center, Duarte, CA.
Yam
P
P
Wallace
R B
RB
Stock
A D
AD
de Lange
G
G
Knowlton
R G
RG
Brown
V A
VA
Donis-Keller
H
H
Hill
L R
LR
Forman
S J
SJ
D000208:Acute Disease; D000954:Antigens, Surface / Q000032:analysis; D001853:Bone Marrow / Q000276:immunology; D016026:Bone Marrow Transplantation; D002678:Chimera; D004912:Erythrocytes / Q000276:immunology; D006086:Graft vs Host Disease; D006412:Hematopoietic Stem Cells / Q000166:cytology*; D006801:Humans; D007126:Immunoglobulin Allotypes / Q000032:analysis; D007938:Leukemia / Q000628:therapy*; D014184:Transplantation, Homologous
D000954:Antigens, Surface; D007126:Immunoglobulin Allotypes